|Daily Range||$36.70 - $37.00|
|52-Week Range||$30.48 - $38.71|
|Dividend (Yield)||$0.00 (2.5%)|
|Average Daily Volume||680,356|
|Current FY EPS||$2.05|
Partnered with Roche-Genentech, Exelixis should be able to charge more than GlaxoSmithKline for its Melanoma treatment.
Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, and Merck top the charts.
Roche looks to maintain leadership into a new generation of oncology.
Gilead's (GILD) expanding oncology pipeline could give investors some exciting opportunities.
While the partnership between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND) seems to be moving forward, the partnership between Roche (OTCMKTS: RHHBY) and PDL (NASDAQ: PDLI) has seemingly reached its end
AstraZeneca reported disappointing fourth quarter revenues but showed progress with an Alzheimer's therapy the company has under development.
Iclusig has taken quite a few knocks since October, but there are three ways Ariad could rebuild the brand's value and boost shareholder value in the process.
Here’s how to post a 28.6% profit loss, miss estimates, and still beat the S&P 500.